company background image
ERAS

Erasca NasdaqGS:ERAS Stock Report

Last Price

US$4.04

Market Cap

US$606.2m

7D

3.9%

1Y

-65.9%

Updated

30 Jan, 2023

Data

Company Financials +

ERAS Stock Overview

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

ERAS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Erasca, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Erasca
Historical stock prices
Current Share PriceUS$4.04
52 Week HighUS$12.80
52 Week LowUS$3.60
Beta0
1 Month Change-6.26%
3 Month Change-49.56%
1 Year Change-65.91%
3 Year Changen/a
5 Year Changen/a
Change since IPO-76.82%

Recent News & Updates

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Oct 20

Recent updates

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12
We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Shareholder Returns

ERASUS BiotechsUS Market
7D3.9%0.8%2.8%
1Y-65.9%7.1%-9.2%

Return vs Industry: ERAS underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ERAS underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is ERAS's price volatile compared to industry and market?
ERAS volatility
ERAS Average Weekly Movement12.3%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: ERAS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ERAS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2018123Jonathan Limhttps://www.erasca.com

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme.

Erasca, Inc. Fundamentals Summary

How do Erasca's earnings and revenue compare to its market cap?
ERAS fundamental statistics
Market CapUS$606.22m
Earnings (TTM)-US$138.02m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ERAS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$138.02m
Earnings-US$138.02m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.92
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ERAS perform over the long term?

See historical performance and comparison